Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: L15 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety of CT-P13 (Infliximab Biosimilar) over Two Years in Patients with Ankylosing Spondylitis: Comparison Between Continuing with CT-P13 and Switching from Infliximab to CT-P13
Won Park¹, Pedro Miranda², Marek Brzosko³, Piotr Wiland⁴, Sergio Gutierrez-Ureña⁵, Helena Mikazane⁶, Yeon-Ah Lee⁷, Svitlana Smiyan⁸, Mie-Jin Lim¹, Vladimir Kadinov⁹, Carlos Abud-Mendoza¹⁰, YoungKi Son¹¹, Dae-Hyun Yoo¹² and Jürgen Braun¹³, ¹Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ²Universidad de Chile and Centro de Estudios Reumatologicos, Santiago de Chile, Chile, ³Department of Rheumatology and Internal Diseases, Department of Rheumatology and Internal Diseases Pomeranian Medical University in Szczecin, Szczecin, Poland, ⁴Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ⁵Antiguo Hospital Civil de Guadalajara, Guadalajara, Mexico, ⁶Outpatient Clinic 'ORTO', Riga, Latvia, ⁷Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, ⁸Municipal Institution of Ternopil Regional Council "Ternopil University Hospital", Ternopil, Ukraine, ⁹Multiprofile Hospital for Active Treatment 'Sv. Marina', Varna, Bulgaria, ¹⁰Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosyi, Mexico, ¹¹CELLTRION, Incheon, South Korea, ¹²Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹³PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose: CT-P13 is an infliximab (INX) biosimilar recently approved by the European Medicine Agency. PLANETAS was a 54-week (wk) randomized double-blind parallel group multicenter Phase…
Abstract Number: 2888 • 2013 ACR/ARHP Annual Meeting
Frequent Detection Of Inflammation and Fat Infiltration Suggestive Of Spondyloarthritis On MRI Of The Entire Spine In Healthy Subjects and Patients With Mechanical Back Pain
Ulrich Weber¹, Zheng Zhao², Veronika Zubler³, Stanley Chan⁴, Robert GW Lambert⁵, Mikkel Ostergaard⁶, Susanne Juhl Pedersen⁷, Kaspar Rufibach⁸ and Walter P. Maksymowych⁹, ¹Rheumatology, Balgrist University Hospital, Zurich, Switzerland, ²Department of Rheumatology, University of Alberta and PLA General Hospital, Beijing, PR China, Beijing, AB, China, ³Radiology, Balgrist University Hospital, Zurich, Switzerland, ⁴Division of Ophthalmology, University of Alberta, Edmonton, AB, Canada, ⁵Radiology, University of Alberta, Edmonton, AB, Canada, ⁶Copenhagen Center for Arthritis Research, Glostrup, Denmark, ⁷Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ⁸rePROstat, Basel, Switzerland, ⁹Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Mechanical back pain (MBP) patients and healthy subjects may show spinal MRI lesions suggestive for spondyloarthritis (SpA) such as corner inflammatory lesions (CIL) or…
Abstract Number: 2456 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Overweight and Obesity and The Relation To Disease Activity, Physical Function and Quality Of Life In Patients With Axial Spondyloarthritis
Fiona Maas¹, Anneke Spoorenberg¹, Eveline van der Veer², Reinhard Bos³, Monique Efde³, Hendrika Bootsma⁴, Elisabeth Brouwer⁵ and Suzanne Arends^3,4, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands, ³Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ⁴Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁵Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Obesity is a growing problem in Western society. It is associated with an increased risk for many disorders, impaired functional capacity, and impaired quality…
Abstract Number: 2042 • 2013 ACR/ARHP Annual Meeting
Pregnancy Outcomes In Women With Rheumatologic Conditions Exposed To Infliximab
Sirisha Kalari¹, Fredrik Granath², Chun-Yuan Guo¹, Diane D. Harrison¹, Gabriella Bröms², Anja Geldhof³, Riikka Nissinen³, Marilyn Sanders¹, Mika Gissler⁴, Lars Pedersen⁵, Henrik Toft Sorensen⁵ and Helle Kieler², ¹Janssen Research & Development, LLC., Horsham, PA, ²Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden, ³Janssen Biologics Europe, Leiden, Netherlands, ⁴Information Department, National Institute for Health and Welfare, Helsinki, Finland, ⁵Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: RA, AS, and PsA are approved indications for infliximab (IFX). In the US, IFX is a pregnancy Category B drug. For RA and some…
Abstract Number: 1526 • 2013 ACR/ARHP Annual Meeting
Stable Clinical and MRI Response In Patients With Early Axial Spondyloarthritis After 3 Years Of Continuous Treatment With Etanercept, Data Of The Esther Trial
In-Ho Song¹, Kay-Geert A. Hermann², Hildrun Haibel¹, Christian Althoff³, Denis Poddubnyy⁴, Joachim Listing⁵, Anja Weiss⁶, Ekkehard Lange⁷, Bruce Freundlich⁸, Martin Rudwaleit⁹ and Joachim Sieper⁴, ¹Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ²Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ³Radiology, Charite Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵German Rheumatism Research Center, Berlin, Germany, ⁶German Rheumatism Research Centre, Berlin, Germany, ⁷BU Specialty Care, Pfizer Pharma AG, Berlin, Germany, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Endokrinologikum, Berlin, Germany
Background/Purpose: < style="text-align: justify;">In patients with early axial spondyloarthritis (SpA) with a disease duration of 10 years) where BASDAI50 response rates of 47%…
Abstract Number: 1119 • 2013 ACR/ARHP Annual Meeting
Quantification Of Inflammatory Disease Of Spine In Ankylosing Spondylitis Using Volumetric Magnetic Resonance Imaging Analysis
Ejaz Pathan¹, Adrian Lim², Andy Graham³, Keshthra Satchithananda², Dobrina Hull⁴, Sonya Abraham⁵, Anshul Rastogi⁶, Andrew Keat⁷, Mark Hinton⁸, Olga Kubassova⁹, Peter C. Taylor¹⁰ and J.V. Hajnal¹¹, ¹Clinical Trials Unit, Kennedy Institute of Rheumatology, London W6 8RF, United Kingdom, ²Radiology, Imperial College Healthcare NHS Trust, London, United Kingdom, ³QABC Minster House, Image Analysis, London, United Kingdom, ⁴Clinical Trials Unit, The Kennedy Institute of Rheumatology, London, United Kingdom, ⁵Rheumatology, Charing Cross Hospital, Imperial college NHS trust London UK, London W6 8RF, United Kingdom, ⁶Radiology, Barts and the London NHS Trust, London, United Kingdom, ⁷Rheumatology, Northwick Park Hospital, Harrow, United Kingdom, ⁸Image Analysis Ltd, London, United Kingdom, ⁹Image Analysis Ltd., Leeds, United Kingdom, ¹⁰NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ¹¹Division of Imaging Sciences, King's College London, London, United Kingdom
Background/Purpose: To develop methodology for quantification of spinal inflammation in AS using a volumetric MRI-based technique and to explore relationships between these findings and clinical measures…
Abstract Number: 2219 • 2012 ACR/ARHP Annual Meeting
Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Show Similar Response Rates After One Year of Treatment with Etanercept – results of the Esther Trial
In-Ho Song¹, Kay-Geert A. Hermann², Hildrun Haibel¹, Christian Althoff³, Denis Poddubnyy⁴, Joachim Listing⁵, Anja Weiß⁶, Ekkehard Lange⁷, Bruce Freundlich⁸, Martin Rudwaleit⁹ and Joachim Sieper¹⁰, ¹Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ²Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ³Radiology, Charite Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵German Rheumatism Research Center, Berlin, Germany, ⁶German Rheumatism Research Centre, Berlin, Germany, ⁷BU Specialty Care, Pfizer Pharma AG, Berlin, Germany, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Endokrinologikum Berlin, Berlin, Germany, ¹⁰Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany
Background/Purpose: In patients with early axial spondyloarthritis (SpA) with a disease duration < 5 years we assessed whether there is a difference to etanercept (ETA)…
Abstract Number: 1363 • 2012 ACR/ARHP Annual Meeting
Validation of the Self-Administered Comorbidity Questionnaire in Patients with Ankylosing Spondylitis
Carmen Stolwijk¹, A.M. Van Tubergen², Sofia Ramiro³, Ivette Essers¹, Marc Blaauw¹, Désirée van der Heijde⁴, Robert B. M. Landewé⁵, Filip Van den Bosch⁶, Maxime Dougados⁷ and Annelies Boonen⁸, ¹Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²Department of Medicine, Maastricht University Medical Center, Maastricht, Netherlands, ³Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, ⁶Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁷Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁸Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: Comorbidities can importantly influence the results of clinical studies on functional outcomes as they may act as confounders or effect modifiers. The generic self-administered…
Abstract Number: 571 • 2012 ACR/ARHP Annual Meeting
Description of Distribution of Active Inflammatory Lesions On Magnetic Resonance Imaging of the Sacroiliac Joints and the Spine in Patients with Early Axial Spondyloarthritis – Analysis of the Esther Trial Baseline Data
In-Ho Song¹, Christian Althoff², Hildrun Haibel¹, Joachim Listing³, Anja Weiß⁴, Bruce Freundlich⁵, Martin Rudwaleit⁶ and Joachim Sieper⁷, ¹Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ²Radiology, Charite Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ³German Rheumatism Research Center, Berlin, Germany, ⁴German Rheumatism Research Centre, Berlin, Germany, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Endokrinologikum Berlin, Berlin, Germany, ⁷Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany
Background/Purpose: To address the question whether active inflammation starts at specific sites of the sacroiliac joints (SI-joints) and/ or the spine. Methods: Wb-MRIs of…
Abstract Number: 2220 • 2012 ACR/ARHP Annual Meeting
Development of the Pulsar (Program to Understand the Longterm Outcomes in Spondyloarthritis) Registry
Andreas M. Reimold¹, Liron Caplan², Daniel O. Clegg³, Gail S. Kerr⁴, Elizabeth Chang⁵, Lisa A. Davis⁶, Prashant Kaushik⁷, Vikas Majithia⁸, J. Steuart Richards⁹, Joel D. Taurog¹⁰ and Jessica Walsh¹¹, ¹Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ²Div of Rheumatology, Denver VA and Univ of Colorado School of Medicine, Aurora, CO, ³Division of Rheumatology, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ⁴Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ⁵Phoenix VAHCS, Phoenix, AZ, ⁶Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO, ⁷Department of Medicine, Sratton VAMC, Albany, NY, ⁸Div of Rheumatology, University of Mississippi Medical Center, Jackson, MS, ⁹Rheumatology, Washington DC VA and Georgetown University, Washington, DC, ¹⁰Internal Medicine, Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ¹¹Rheumatology, University of Utah Hospital, Salt Lake City, UT
Background/Purpose: The spondyloarthritides are a group of conditions characterized by inflammation in the axial skeleton or peripheral joints. The arthritis may present as the primary…
Abstract Number: 1366 • 2012 ACR/ARHP Annual Meeting
Golimumab Administered Subcutaneously Every 4 Weeks in Chinese Patients with Active Ankylosing Spondylitis: Week 24 Safety and Efficacy Results From a Randomized, Placebo – Controlled Study
Chunde Bao¹, Feng Huang², Muhammad Asim Khan³, Kaiyin Fei⁴, Zhong Wu⁴ and Elizabeth C. Hsia⁴, ¹Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, ²Dept of Rheumatology, Chinese PLA General Hospital, Beijing, China, ³Medicine/ Rheumatology, Case Western Reserve University Hospital, Cleveland, OH, ⁴Janssen Research & Development, LLC., Spring House, PA
Golimumab Administered Subcutaneously Every 4 Weeks in Chinese Patients with Active Ankylosing Spondylitis: Week 24 Safety and Efficacy Results From a Randomized, Placebo-Controlled StudyBackground/Purpose: This…
Abstract Number: 575 • 2012 ACR/ARHP Annual Meeting
Profiling of Response to Anti-TNFα Therapy by Serum Markers of Tissue Degradation End Products in Ankylosing Spondylitis Patients
Anne Sofie Siebuhr¹, Anne C. Bay-Jensen², Morten Asser Karsdal³, Efstathios Vassiliadis⁴, Stephanie Wichuk⁵, Claus Christiansen⁶ and Walter P. Maksymowych⁷, ¹Rheumatology, Nordic Bioscience, Herlev, Denmark, ²Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ³Nordic Bioscience A/S, Herlev, Denmark, ⁴Nordic Bioscience, Herlev, Denmark, ⁵Medicine, University of Alberta, Edmonton, AB, Canada, ⁶CCBR, Ballerup, Denmark, ⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Chronic inflammatory diseases such as Ankylosing Spondylitis (AS) are diverse and therefore hard to clearly diagnose and treat. Conventional biomarkers for AS, as CRP…
Abstract Number: 1925 • 2012 ACR/ARHP Annual Meeting
Patient Satisfaction and Experience with Golimumab, Adalimumab, and Etanercept for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Susan Bolge¹, Helen Eldridge², Dilesh Doshi¹, Lorie Ellis³, Barbara Roland⁴ and John Woelfel⁴, ¹Janssen Scientific Affairs, LLC, Horsham, PA, ²Janssen Services, LLC., Titusville, NJ, ³Health Economics & Outcomes Research, Janssen Scientific Affairs, LLC, Horsham, PA, ⁴The Dominion Group, Reston, VA
Title: Patient Satisfaction and Experience with Golimumab, Adalimumab, and Etanercept for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis Background/Purpose: Golimumab (GLM), adalimumab…
Abstract Number: 1372 • 2012 ACR/ARHP Annual Meeting
Increased Participation in Daily Activities After 24 Weeks of Certolizumab Pegol Treatment of Axial Spondyloarthritis Patients, Including Patients with Ankylosing Spondylitis: Results of a Phase 3 Double-Blind Randomized Placebo-Controlled Study
Désirée van der Heijde¹, Jürgen Braun², Martin Rudwaleit³, Oana Purcaru⁴ and Arthur Kavanaugh⁵, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Endokrinologikum Berlin, Berlin, Germany, ⁴UCB Pharma, Braine, Belgium, ⁵UCSD School of Medicine, La Jolla, CA
Background/Purpose: Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS) and non-radiographic axial SpA (nr-axSpA). AS significantly affects patients' (pts) work productivity.1 The impact of the…
Abstract Number: 583 • 2012 ACR/ARHP Annual Meeting
Familial Aggregation and Heritability of Ankylosing Spondylitis in Taiwan: A Nationwide Population Study
Chang-Fu Kuo¹, Matthew J. Grainge², Lai-Chu See³, Kuang-Hui Yu⁴, Shue-Fen Luo⁴, Ana M. Valdes⁵, I-Jun Chou⁶, Weiya Zhang¹ and Michael Doherty⁷, ¹Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, United Kingdom, ²Division of Epidemiology and Public Health, School of Community Health Sciences, University of Nottingham, Nottingham, United Kingdom, ³Department of Public Health, College of Medicine, Chang Gung University, Taoyuan, Taiwan, ⁴Division of Rheumatology, Immunology and Allergy, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁵Dept of Twin Research and Genetic Epidemiology, St. Thomas' Hospital, King's College London, London, United Kingdom, ⁶Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁷Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom
Background/Purpose: To estimate the risk of ankylosing spondylitis (AS) among individuals with affected first-degree relatives and to assess the magnitude of genetic contribution to the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].